Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

被引:275
作者
Bedimo, Roger [1 ,2 ]
Maalouf, Naim M. [2 ]
Zhang, Song [2 ]
Drechsler, Henning [1 ,2 ]
Tebas, Pablo [3 ]
机构
[1] VA N Texas Healthcare Syst, Dept Med, Dallas, TX USA
[2] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA
[3] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
关键词
cumulative exposure; osteoporotic fractures; protease inhibitors; tenofovir; BONE-MINERAL DENSITY; HIV-INFECTED PATIENTS; THERAPY; PREVALENCE; ADULTS; DISEASE; MARKERS; AIDS;
D O I
10.1097/QAD.0b013e32835192ae
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Background: Whereas tenofovir (TDF) exposure has been associated with decreased bone density, it remains unclear whether it is associated with increased risk of osteoporotic fractures. Methods: Patients with any osteoporotic fracture (defined as wrist, vertebral or hip fracture) occurring after HIV diagnosis were identified by International Classification of Diseases - 9th Revision (ICD-9) code in the Veterans Affairs' Clinical Case Registry from 1988 to 2009. Osteoporotic fracture risk associated with cumulative exposure to TDF and other antiretrovirals was examined in univariate analysis and multivariate model 1 (MV1 - controlling for race, age, tobacco use, diabetes, body mass index, and hepatitis C status) and model 2 (MV2 - controlling for MV1 variables + concomitant antiretroviral exposures). Results: Among 56 660 patients evaluated, TDF exposure (total 46 062 person-years) was associated with an osteoporotic fracture hazard ratio of 1.080 [95% confidence interval (CI) 1.02-1.15, P < 0.001] in univariate analysis, 1.06 (0.99-1.12) in MV1 and 1.06 (0.99-1.14) in MV2. Among patients entering the cohort in the highly active antiretroviral therapy (HAART) era (n = 32 439), TDF exposure was associated with a yearly hazard ratio for osteoporotic fracture of 1.16 (95% CI 1.08-1.24, P < 0.001) in univariate model, 1.13 (1.05-1.21, P = 0.001) in MV1 and 1.12 (1.03-1.21, P = 0.011) in MV2. Boosted protease inhibitor exposure was associated with hazard ratio of 1.11 (1.05-1.18, P = 0.001) in univariate model, 1.08 (1.01-1.15, P = 0.026) in MV1 and 1.05 (0.97-1.13, P = 0.237) in MV2. Among protease inhibitors, lopinavir/ritonavir (LPV/RTV) had an osteoporotic fracture hazard ratio of 1.09 (CI 1.00-1.20, P = 0.051) in MV2. Conclusion: Cumulative exposure to TDF and, among protease inhibitors, LPV/RTV was independently predictive of increased risk of osteoporotic fracture in the HAART era. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:825 / 831
页数:7
相关论文
共 27 条
[1]
[Anonymous], 2011, C RETR OPP INF BOST
[2]
[Anonymous], 18 C RETR OPP INF BO
[3]
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [J].
Brown, Todd T. ;
Qaqish, Roula B. .
AIDS, 2006, 20 (17) :2165-2174
[4]
Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy [J].
Bruera, D ;
Luna, N ;
David, DO ;
Bergoglio, LA ;
Zamudio, J .
AIDS, 2003, 17 (13) :1917-1923
[5]
Reduced bone mineral density in HIV-infected patients:: prevalence and associated factors [J].
Cazanave, Charles ;
Dupon, Michel ;
Lavignolle-Aurillac, Valerie ;
Barthe, Nicole ;
Lawson-Ayayi, Sylvie ;
Mehsen, Nadia ;
Mercie, Patrick ;
Morlat, Phillipe ;
Thiebaut, Rodolphe ;
Dabis, Francois .
AIDS, 2008, 22 (03) :395-402
[6]
Reduced bone density in HIV-infected women [J].
Dolan, SE ;
Huang, JS ;
Killilea, KM ;
Sullivan, MP ;
Aliabadi, N ;
Grinspoon, S .
AIDS, 2004, 18 (03) :475-483
[7]
Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection [J].
El-Maouche, Diala ;
Mehta, Shruti H. ;
Sutcliffe, Catherine ;
Higgins, Yvonne ;
Torbenson, Michael S. ;
Moore, Richard D. ;
Thomas, David L. ;
Sulkowski, Mark S. ;
Brown, Todd T. .
JOURNAL OF HEPATOLOGY, 2011, 55 (04) :770-776
[8]
Risk of osteoporotic fracture in elderly patients taking warfarin - Results from the National Registry of Atrial Fibrillation 2 [J].
Gage, BF ;
Birman-Deych, E ;
Radford, MJ ;
Nilasena, DS ;
Binder, EF .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (02) :241-246
[9]
Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].
Gallant, JE ;
Staszewski, S ;
Pozniak, AL ;
DeJesus, E ;
Suleiman, JMAH ;
Miller, MD ;
Coakley, DF ;
Lu, B ;
Toole, JJ ;
Cheng, AK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201
[10]
Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis [J].
Gallego-Rojo, FJ ;
Gonzalez-Calvin, JL ;
Muñoz-Torres, M ;
Mundi, JL ;
Fernandez-Perez, R ;
Rodrigo-Moreno, D .
HEPATOLOGY, 1998, 28 (03) :695-699